** Shares of Australia's Neurizon Therapeutics NUZ.AX rise as much as 3.1% to A$0.1, their highest level since February 19

** Stock on track to record its third straight session of gains, if the trend holds

** Biotech company posts HY loss attributable to A$5.5 million ($3.90 million), compared with a loss of A$7.3 million in the prior corresponding period

** Posts increase in HY revenue to A$6 million from A$1.8 million last year

** Stock has risen 14.1% this year, including session moves

($1 = 1.4120 Australian dollars)

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com;))